๐๐จ๐ง๐๐จ๐ญ๐ญ๐ข๐๐ ๐๐ง๐ฏ๐๐ฌ๐ญ๐ฌ ๐ข๐ง ๐๐ ๐๐ฒ๐๐ฌ ๐ญ๐จ ๐๐ฑ๐ฉ๐๐ง๐ ๐.๐. ๐๐๐ซ๐ค๐๐ญ...
๐๏ธ Presbyopia News ๐
๐ ๐๐ฅ๐๐จ๐ง ๐๐๐ฎ๐ง๐๐ก๐๐ฌ ๐๐ฅ๐๐ซ๐๐จ๐ง ๐๐๐ง๐๐ฉ๐ญ๐ข๐ฑ ๐๐ซ๐จ ๐๐ซ๐ข๐๐จ๐๐๐ฅ ๐๐๐ ๐ข๐ง ๐ญ๐ก๐ ๐.๐.
Alcon is redefining presbyopia correction with the U.S. launch of its Clareon PanOptix Pro Trifocal IOLโan advanced intraocular lens designed to deliver exceptional vision at near, intermediate, and far distances. Built to address the challenges of presbyopia, this lens helps patients regain seamless visual range and reduce dependence on glasses. Featuring ENLIGHTEN Optical Technology, it offers 94% light utilisation and reduced light scatter, enhancing contrast and clarity in all lighting conditions. Delivered via the Clareon AutonoMe preloaded system, it ensures precise and efficient implantation. U.S. commercial rollout begins in May 2025, with international availability to follow.
๐ ๐๐ซ๐๐ฌ๐ข๐ฌ ๐๐๐ฎ๐ง๐๐ก๐๐ฌ ๐๐๐๐๐โข ๐๐ฒ๐ ๐๐ซ๐จ๐ฉ๐ฌ ๐๐จ๐ซ ๐๐ซ๐๐ฌ๐๐ฒ๐จ๐ฉ๐ข๐ ๐ข๐ง ๐ญ๐ก๐ ๐.๐.
Orasis Pharmaceuticals has launched QLOSIโข (pilocarpine hydrochloride ophthalmic solution) 0.4% in the U.S. to treat presbyopia. These preservative-free eye drops improve near vision by using a pinhole effect to adjust pupil size, while maintaining clear distance vision. QLOSI works within 20 minutes and lasts 8-12 hours. Itโs recommended to use one drop per eye, up to twice daily, and remove contact lenses before application.
๐ ๐๐ฅ๐๐จ๐ง ๐๐๐ฎ๐ง๐๐ก๐๐ฌ ๐๐ฅ๐๐ซ๐๐จ๐ง ๐๐๐ง๐๐ฉ๐ญ๐ข๐ฑ ๐๐ซ๐จ ๐๐ซ๐ข๐๐จ๐๐๐ฅ ๐๐๐ ๐ข๐ง ๐ญ๐ก๐ ๐.๐.
Alcon is redefining presbyopia correction with the U.S. launch of its Clareon PanOptix Pro Trifocal IOLโan advanced intraocular lens designed to deliver exceptional vision at near, intermediate, and far distances. Built to address the challenges of presbyopia, this lens helps patients regain seamless visual range and reduce dependence on glasses. Featuring ENLIGHTEN Optical Technology, it offers 94% light utilisation and reduced light scatter, enhancing contrast and clarity in all lighting conditions. Delivered via the Clareon AutonoMe preloaded system, it ensures precise and efficient implantation. U.S. commercial rollout begins in May 2025, with international availability to follow.
๐ ๐๐ซ๐๐ฌ๐ข๐ฌ ๐๐๐ฎ๐ง๐๐ก๐๐ฌ ๐๐๐๐๐โข ๐๐ฒ๐ ๐๐ซ๐จ๐ฉ๐ฌ ๐๐จ๐ซ ๐๐ซ๐๐ฌ๐๐ฒ๐จ๐ฉ๐ข๐ ๐ข๐ง ๐ญ๐ก๐ ๐.๐.
Orasis Pharmaceuticals has launched QLOSIโข (pilocarpine hydrochloride ophthalmic solution) 0.4% in the U.S. to treat presbyopia. These preservative-free eye drops improve near vision by using a pinhole effect to adjust pupil size, while maintaining clear distance vision. QLOSI works within 20 minutes and lasts 8-12 hours. Itโs recommended to use one drop per eye, up to twice daily, and remove contact lenses before application.
